Filter
550
Featured
Recommendations
140
New Publications
3
Language
Document type
Guidelines
283
Fact sheets
90
Studies & Reports
55
Manuals
41
Infographics
22
Videos
14
Resource Platforms
13
Online Courses
13
Training Material
10
Situation Updates
5
Brochures
2
No document type
2
Countries / Regions
Russia
50
Brazil
44
Germany
29
Latin America and the Carribbean
27
Middle East and North Africa
22
Mozambique
21
Angola
21
West and Central Africa
21
Guinea-Bissau
16
East and Southern Africa
16
Africa
13
Global
11
Syria
10
Yemen
10
Eastern Europe and Central Asia
10
Spain
9
South Africa
7
Ecuador
5
Western and Central Europe
5
Eastern Europe
5
India
4
South Sudan
3
Argentina
3
Western Pacific Region
3
Vietnam
3
France
3
Nigeria
2
Haiti
2
Philippines
2
Sudan
2
Ukraine
2
South–East Asia Region
2
Kazakhstan
2
Portugal
2
Burkina Faso
1
Senegal
1
Mali
1
Côte d’Ivoire / Ivory Coast
1
Saudi Arabia
1
Ethiopia
1
Cameroon
1
Niger
1
Togo
1
Somalia
1
Nepal
1
Turkey
1
Chad
1
Cambodia
1
China
1
Bangladesh
1
Benin
1
Central African Republic
1
Austria
1
Switzerland
1
Burundi
1
El Salvador
1
Bolivia
1
Madagascar
1
Luxembourg
1
Venezuela
1
Italy
1
Djibouti
1
Laos
1
Congo-Brazzaville
1
Canada
1
Belgium
1
United Kingdom
1
Authors & Publishers
Publication Years
Category
Countries
224
Clinical Guidelines
31
Pharmacy & Technologies
21
Women & Child Health
16
Capacity Building
9
Key Resources
4
Public Health
2
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement
...
22. Februar 2021
Das Epidemiologische Bulletin 8/2021 beschreibt die Chancen, aber auch Risiken und Limitationen bei der Eigenanwendung von Antigen-Selbsttests zum Nachweis einer akuten Infektion mit SARS-CoV-2.
19 February 2021
The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the class effect of anti-IL-6 therapies. It will also es
...
wird ständig aktualisiert
Policy Brief.
Our understanding of how to diagnose and manage Long COVID is still evolving but the condition can be very debilitating. It is associated with a range of overlapping symptoms including generalized chest and muscle pain, fatigue, shortness of breath, and cognitive dysfunction, and the
...
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv
...
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv
...
WHO Living guideline: Drugs to prevent COVID-19
recommended
Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform
...
04.März 2021
MEDBOX Issue Brief no. 10
Dieser Issue Brief gibt einen kurzen Überblick über Teststrategie, Testverfahren, Videos zur Handhabung und weiterführende Literatur.
Actualizadas en el documento titulado «Vigilancia de salud pública en relación con la COVID-19» publicado el 16 de diciembre de 2020
Обновление рекомендаций по санитарно-эпидемиологическому надзору за COVID-19 от
16 декабря 2020 г
Actualisées dans « La surveillance de la santé publique dans le contexte de la COVID-19 », publié le 16 décembre 2020
Основные аспекты обеспечения биологической безопасности в лабораторных условиях в связи с распространением вируса SARS-CoV
28 January 2021. The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients.
28 Jan. 2021. L’objet de ce document est de fournir des orientations provisoires sur la sécurité biologique en laboratoire applicable à l’analyse d’échantillons cliniques issus de patients.
23 February 2021
This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc
...
23 February 2021
This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc
...
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
This document is also available in Arabic and Portuguese.
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
